Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tafoxiparin (Primary)
- Indications Labour induction
- Focus Therapeutic Use
- Sponsors Dilafor
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 21 Aug 2019 This trial is completed in Sweden as per European Clinical Trials Database.
- 18 Jul 2019 This trial is completed in Denmark as per European Clinical Trials Database.